Skip to main content
RT @ericdeinmd: Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE
Higher copays associated w/:
💊39% lower odds of H

Eric Dein ericdeinmd

3 years 11 months ago
Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE Higher copays associated w/: 💊39% lower odds of HCQ adherence 💊56% lower AZA adherence 💊32% lower MMF adherence Need better $$ and transparency into costs. Screen for determinants of health affecting affordability! @Rheumnow https://t.co/1NdBb3GLzL
RT @uptoTate: Abs 0829 at #ACR22 finds AOSD more commonly affects caucasian females. Also notes abnormal labs include el

Dr. Rachel Tate uptoTate

3 years 11 months ago
Abs 0829 at #ACR22 finds AOSD more commonly affects caucasian females. Also notes abnormal labs include elevated inflammatory markers, leukocytosis, and anemia. @RheumNow https://t.co/1Nr8C5dX3G
RT @RHEUMarampa: There's a lot of Scleroderma-like fibrosing skin disorders!
#ACR22 @RheumNow #RheumTwitter @rheumarhyme

sheila RHEUMarampa

3 years 11 months ago
There's a lot of Scleroderma-like fibrosing skin disorders! #ACR22 @RheumNow #RheumTwitter @rheumarhyme https://t.co/W1AEtfeKZc
RT @uptoTate: Serum AMH reduced in adolescents w/ rheumatic disease compared to menstrual-age matched, healthy controls.

Dr. Rachel Tate uptoTate

3 years 11 months ago
Serum AMH reduced in adolescents w/ rheumatic disease compared to menstrual-age matched, healthy controls. UCTD and SLE higher disease activity assoc'd w/ dec AMH levels, suggesting dz activity and dz may affect ovarian reserve. Abs 0942 #ACR22 @RheumNow https://t.co/xSZ85ipFSD https://t.co/tsaWBdrQcb
RT @EBRheum: Excllent plenary, medication copay modifies treatment adherence in SLE

>$10 copay reduced adherence fo

Mike Putman EBRheum

3 years 11 months ago
Excllent plenary, medication copay modifies treatment adherence in SLE >$10 copay reduced adherence for HCQ (39%), AZA (56%), MMF (32%) Easy to imagine that all our innovation cannot overcome access & barriers Should be priority to fix #ACR22 @RheumNow #ACRBest Abstr#1115 https://t.co/BPfr9mCVgy
RT @DrTrishHarkins: Congenital ❤️ Block in Ro/La pregnancies

Abst#0957
👉1st echo @ mean 20wk
👉CHB 3/47- all

Patricia Harkins DrTrishHarkins

3 years 11 months ago
Congenital ❤️ Block in Ro/La pregnancies Abst#0957 👉1st echo @ mean 20wk 👉CHB 3/47- all on 1st echo 👉 1 reversed 3rd ➡️ 1st AVB post dexamethasone 🔥Key messages🔥 🤰serial echo should start @ 16-18wk gestation 👶 early detection ⬆️ outcomes #ACR22 @RheumNow
RT @uptoTate: Combined estrogen-progestin contraception in SLE patients with positive aPL conferred an increased risk of

Dr. Rachel Tate uptoTate

3 years 11 months ago
Combined estrogen-progestin contraception in SLE patients with positive aPL conferred an increased risk of thrombosis relative to progestin-only contraception. Abs 0943 #ACR22 @RheumNow https://t.co/B2Wmhlz6at https://t.co/YlvqoYY8FN
RT @RHEUMarampa: 🖊️Eosinophilic fasciitis is not assoc. w/ RP
🖊️On biopsy, extends to SC fat and fascia
🖊ï¸

sheila RHEUMarampa

3 years 11 months ago
🖊️Eosinophilic fasciitis is not assoc. w/ RP 🖊️On biopsy, extends to SC fat and fascia 🖊️CS are 1st line tx; remission is the rule but takes a while so SLOWLY taper steroids #ACR22 @Rheumnow #RheumTwitter https://t.co/Z26Gim9JUW
RT @uptoTate: Use of pregnancy-compatible medication and control of disease activity with lower glucocorticoid doses in

Dr. Rachel Tate uptoTate

3 years 11 months ago
Use of pregnancy-compatible medication and control of disease activity with lower glucocorticoid doses in PM/DM pregnancies may be important to achieve good pregnancy outcomes. Abs 0952 #ACR22 @RheumNow https://t.co/LMfebb4GE1 https://t.co/0gYG245BXV
RT @Yuz6Yusof: #ACR22 Plenary II Abstr#1114 Access to therapy/Cost need to be improved since high copays (=> 10USD pe

Md Yuzaiful Md Yusof Yuz6Yusof

3 years 11 months ago
#ACR22 Plenary II Abstr#1114 Access to therapy/Cost need to be improved since high copays (=> 10USD per month) affects adherence to treatment (HCQ, AZA, MMF but not MTX) in #lupus @RheumNow https://t.co/WnwIhpqDxL
RT @ericdeinmd: Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE?
363 pt P2, double-blind PBO-controlled 48 w

Eric Dein ericdeinmd

3 years 11 months ago
Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE? 363 pt P2, double-blind PBO-controlled 48 wk study DEUC 3 mg BID, 6 BID, 12 QB vs PBO: At 32wk: DEUC 3BID & 6BID > PBO, sustained across all groups at 48wk. AEs: similar bw PBO and DEUC. No VTE @RheumNow #ACRBest https://t.co/uamJe05odq
RT @RHEUMarampa: Scleredema has an indolent course
Affected skin is doughy
Has 3 clinical subgrps:
💠classic adultoru

sheila RHEUMarampa

3 years 11 months ago
Scleredema has an indolent course Affected skin is doughy Has 3 clinical subgrps: 💠classic adultorum - self-limited, +visceral involvement 💠blood dyscrasia 💠diabetes - visceral involvement is rare #ACR22 @Rheumnow @rheumarhyme https://t.co/ZlQmCc1WYa
RT @uptoTate: Interstitial inflammation in the entire cortical parenchyma in areas w/ and w/o fibrosis identifies at ris

Dr. Rachel Tate uptoTate

3 years 11 months ago
Interstitial inflammation in the entire cortical parenchyma in areas w/ and w/o fibrosis identifies at risk SLE pts for CKD progression. Abs 0634 #ACR22 @RheumNow https://t.co/3iBYHPyYXL https://t.co/iSwblT2Amm
RT @uptoTate: Analysis from Abs 0954 shows that mainly fatigue and back pain have an impact on the mean BASDAI during pr

Dr. Rachel Tate uptoTate

3 years 11 months ago
Analysis from Abs 0954 shows that mainly fatigue and back pain have an impact on the mean BASDAI during pregnancy. #ACR22 @RheumNow https://t.co/l5VGKqF2ar https://t.co/fpkl8VRRJP
Is there finally something new on the horizon in Sjogren’s syndrome? 
×